Arbutus Biopharma (NASDAQ:ABUS) dropped 9% last week. The company and Vaccitech Plc (NASDAQ: VACC) collaborated to study a combination of chronic hepatitis B virus treatment for patients receiving standard-of-care nucleotide reverse transcriptase inhibitor therapy. The companies will assess the pharmacokinetics, immunogenicity, antiviral activity, and safety of the company’s AB-729 combination, followed by Vaccitech’s VTP-300 in …
Continue reading “Arbutus Biopharma (NASDAQ:ABUS) Stock Sees Selling Pressure At Higher Level”